FiercePharma3d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...
Moderna Swings to 3Q Profit, Driven by Updated Covid-19 Vaccine
The biotech company, which makes the Spikevax RNA-based Covid-19 vaccine, reported net income of $13 million, or 3 cents a share, compared with a loss of $3.6 billion, or $9.53 a share, in the same ...
Assessing the efficacy of clinical drugs targeting SARS-CoV-2 main protease
Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the ...